Towards an effective malaria vaccine

Archives of Disease in Childhood

Volumn 92, Issue 6, 2007, Pages 476-479

  Aide, Pedro ^a,b   Bassat, Quique ^b,c   Alonso, Pedro L ^b,c,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Ministérioda Saúde   (Mozambique)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; FMP1 VACCINE; FVO VACCINE; GMZ2 VACCINE; INSECTICIDE; LSA NRC VACCINE; MALARIA VACCINE; PFCP 2.9 VACCINE; RTS S VACCINE; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNITY; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREGNANCY; PRIORITY JOURNAL; REVIEW; SPOROZOITE;

ANIMALS; CHILD; CLINICAL TRIALS; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM;

EID: 34249894231     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2005.092551     Document Type: Review

References (35)

1. Russell PF. Man's mastery of malaria. Oxford: Oxford University Press, 1955.
2. Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004;4(6):327-36.
3. WHO. WHO expert committee on malaria, WHO technical report series 892. Geneva: World Health Organization, 2000.
4. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002;2(9):564-73.
5. Hoffman SL, Miller LH. Perspectives on malaria vaccine development. In: Hoffman SL, ed. Malaria vaccine developments multi-immune response approach. Washington: American Society for Microbiology, 1996:1-13.
6. Bonn D. Filling the vaccine gap. Lancet Infect Dis 2005;5(1):7.
7. Gupta S, Snow RW, Donnelly CA, et al. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5(3):340-3.
8. Webster D, Hill AV. Progress with new malaria vaccines. Bull World Health Organ 2003;81(12):902-9.
9. Raghunath D. Malaria vaccine: are we anywhere close? J Postgrad Med 2004;50(1):51-4.
10. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961;192:733-7.
11. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991;45(3):297-308.
12. Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004;71(Suppl 2):239-47.
13. Rieckmann KH, Beaudoin RL, Cassells JS, et al. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979;57(Suppl 1):261-5.
14. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002;185(8):1155-64.
15. Mueller AK, Labaied M, Kappe SH, et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005;433(7022):164-7.
16. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364(9443):1411-20.
17. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994;344(8931):1175-81.
18. Girard MP, Reed ZH, Friede M, et al. A review of human vaccine research and development: malaria. Vaccine 2007;25(9): 1567-80.
19. Doolan DL, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 2006;6(2):169-85.
20. Yazdani SS, Mukherjee P, Chauhan VS, et al. Immune responses to asexual blood-stages of malaria parasites. Curr Mol Med 2006;6(2):187-203.
21. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004;363(9403):150-6.
22. Van de Perre P, Dedet JP. Vaccine efficacy: winning a battle (not war) against malaria. Lancet 2004;364(9443):1380-3.
23. Greenwood BM. What can be expected from malaria vaccines? Ann Trop Med Parasitol 1997;91(Suppl 1):S9-S13.
24. Greenwood B, Marsh K, Snow R. Why do some African children develop severe malaria? Parasitol Today 1991;7(10):277-81.
25. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419(6906):498-511.
26. Graves P, Gelband H. Vaccines for preventing malaria. Cochrane Database Syst Rev 2003;(1):CD000129.
27. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366(9502):2012-8.
28. Dubovsky F, Rabinovich R. Malaria vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 2004:1282-9.
29. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336(2):86-91.
30. Stoute JA, Gombe J, Withers MR, et al. Phase 1 randomized double-blind safety and immunogenicily trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007;25(1):176-84.
31. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005;73(6):3677-85.
32. Malkin EM, Durbin AP, Diemert DJ, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005;23(24):3131-8.
33. Smith JD, Deitsch KW. Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines. J Exp Med 2004;200(9):1093-7.
34. Schofield L, Hewitt MC, Evans K, et al. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002;418(6899):785-9.
35. Moree M, Ewart S. Policy challenges in malaria vaccine introduction. Am J Trop Med Hyg 2004;71(Suppl 2):248-52.